EXEL Stock Analysis: Buy, Sell, or Hold?
EXEL - Exelixis Inc
$55.85
1.89 (3.50%)
▲
5d:
+4.92%
30d:
+15.06%
90d:
+26.82%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Jul 27, 2026
22d
Get Alerted When EXEL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: EXEL trades at premium valuation expecting 4.8% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: EXEL trades at premium valuation expecting 4.8% growth. Hold existing positions but don't chase. Wait for better entry.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$72.44
Based on 8.5% avg growth
INTRINSIC VALUE TODAY
$44.98
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: EXEL is currently trading at $55.85, which is considered extended relative to its 30-day fair value range of $50.72 to $53.94. From a valuation perspective, the stock is trading at a premium (Forward PE: 14.0) compared to its historical average (12.1). At these levels, the market is pricing in 4.8% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, EXEL is in a strong uptrend. The price is approaching resistance at $56.21. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.5% recently.
Market Sentiment: EXEL has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. However, the stock is trading significantly above the average Wall Street target of $49.50. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, EXEL is in a strong uptrend. The price is approaching resistance at $56.21. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.5% recently.
Market Sentiment: EXEL has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. However, the stock is trading significantly above the average Wall Street target of $49.50. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$50.72 -
$53.94
Company Quality Score
63/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
56.2%
Protect Your Profits
Holding EXEL? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.5%)
- BEARISH: Trading 11.4% above Wall St target ($49.50)
- NEUTRAL: Trading at premium valuation - market expects 4.8% growth which is achievable
Trading Range Analysis
30-Day Trading Range
$50.72 -
$53.94
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$50.80
Resistance Level
$56.21
Current Trend
Strong Uptrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
13.97
Wall Street Target
$49.50
(-11.4%)
Revenue Growth (YoY)
10.0%
Earnings Growth (YoY)
43.6%
Profit Margin
35.1%
Valuation Premium vs History
+4.8% premium
PE vs Historical
14.0 vs 12.1
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+4.8%
(market-implied from PE analysis)
1-Year Target
$58.53
(+5%)
2-Year Target
$61.34
(+10%)
3-Year Target
$64.28
(+15%)
3-Yr Target (if PE normalizes)
(PE: 14→12)
PE COMPRESSION
$55.70
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 12.9%)
$125.48
(+125%)
Base:
(SPY PE: 14.0, Growth: 12.9%)
$80.46
(+44%)
Bear:
(PE: 11.9, Growth: 12.9%)
$68.39
(+23%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (18x PE), but valuation improves significantly next year (14x PE) as earnings recover.
Trailing PE: 17.87 | Current EPS (TTM): $3.02
Bull Case
$78.60
(+41%)
Analyst growth 32.4%, PE expands to 19.7
Base Case
$71.45
(+28%)
Market implied 32.4%, PE stable at 17.9
Bear Case
$36.69
(-34%)
Severe decline -20.0%, PE contracts to 15.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 03, 2026 10:19 PM ET
Data refreshes hourly during market hours. Next update: 11:19 PM
Data refreshes hourly during market hours. Next update: 11:19 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EXEL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
9
Sells
Net
INSIDERS SELLING
Recent Transactions
Dana Aftab
SELL
47918 shares
2026-02-24
Dana Aftab
SELL
29873 shares
2026-02-19
Brenda Hefti
SELL
18669 shares
2026-02-18
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 56 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$106 | 64 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 54 HOLD |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 57 HOLD |
Advanced EXEL Option Strategies
Professional options setups generated by AI based on today's EXEL price and gamma walls.
